- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
NewAmsterdam Pharma Company NV (NAMS)
"NewAmsterdam Pharma Company NV stock price live, this page displays NASDAQ NAMS stock exchange data. View the NAMS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the NewAmsterdam Pharma Company NV real time stock price chart below.
What Is the NewAmsterdam Pharma Company NV Stock Price Today?
The NewAmsterdam Pharma Company NV stock price today is 18.750.
What Is the Stock Symbol for NewAmsterdam Pharma Company NV?
The stock symbol for NewAmsterdam Pharma Company NV is ""NAMS.""
What Stock Exchange Does NewAmsterdam Pharma Company NV Trade On?
NewAmsterdam Pharma Company NV is listed and trades on the NASDAQ stock exchange.
Is NewAmsterdam Pharma Company NV a Good Stock to Buy?
Determining whether NewAmsterdam Pharma Company NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NAMS quote. (ISIN: NL00150012L7)"
What Is the NewAmsterdam Pharma Company NV Stock Price Today?
The NewAmsterdam Pharma Company NV stock price today is 18.750.
What Is the Stock Symbol for NewAmsterdam Pharma Company NV?
The stock symbol for NewAmsterdam Pharma Company NV is ""NAMS.""
What Stock Exchange Does NewAmsterdam Pharma Company NV Trade On?
NewAmsterdam Pharma Company NV is listed and trades on the NASDAQ stock exchange.
Is NewAmsterdam Pharma Company NV a Good Stock to Buy?
Determining whether NewAmsterdam Pharma Company NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NAMS quote. (ISIN: NL00150012L7)"
NASDAQ
Currency in USD
18.750
-0.470(-2.45%)
Closed·
After Hours
18.7500.000(0.00%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.310
19.190
52 wk Range
14.060
27.290
NAMS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NAMS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.31019.190
52 wk Range
14.06027.290
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NAMS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
43.998
Upside
+134.66%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
- NewAmsterdam Pharma appoints Adele Gulfo to Board
- Investing.com
- NewAmsterdam Pharma adds Adele Gulfo to its Board
- Investing.com
NewAmsterdam Pharma Company NV Company Profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NewAmsterdam Pharma Company NV SWOT Analysis
Obicetrapib's Promise | NewAmsterdam Pharma's lead drug candidate shows potential to revolutionize cardiovascular disease treatment, with significant LDL-C reduction and MACE benefits |
Market Opportunity | Analysts project potential U.S. sales exceeding $1.3 billion, with global end-user sales opportunity surpassing $2.5 billion for obicetrapi |
Patent Protection | Robust patent portfolio expected to provide market exclusivity until late 2030s, ensuring long-term revenue potential for NewAmsterdam Pharma |
Analyst Outlook | Price targets range from $29.03 to $52.39, reflecting optimism in obicetrapib's potential despite challenges in regulatory approval and market adoption |
Compare NAMS to Peers and Sector
Metrics to compare | NAMS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNAMSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.5x | −1.0x | −0.5x | |
PEG Ratio | −0.34 | 0.00 | 0.00 | |
Price/Book | 2.8x | 2.8x | 2.6x | |
Price / LTM Sales | 45.7x | 9.7x | 2.9x | |
Upside (Analyst Target) | 129.1% | 305.6% | 53.0% | |
Fair Value Upside | Unlock | 5.7% | 8.9% | Unlock |
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 43.998
(+134.66% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
-0.35 / -0.497
Revenue / Forecast
3.00M / 1.53M
FAQ
What Is the NewAmsterdam Pharma (NAMS) Stock Price Today?
The NewAmsterdam Pharma stock price today is 18.75
What Stock Exchange Does NewAmsterdam Pharma Trade On?
NewAmsterdam Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for NewAmsterdam Pharma?
The stock symbol for NewAmsterdam Pharma is "NAMS."
What Is the NewAmsterdam Pharma Market Cap?
As of today, NewAmsterdam Pharma market cap is 2.10B.
What Is NewAmsterdam Pharma's Earnings Per Share (TTM)?
The NewAmsterdam Pharma EPS (TTM) is -1.85.
When Is the Next NewAmsterdam Pharma Earnings Date?
NewAmsterdam Pharma will release its next earnings report on 11 Aug 2025.
From a Technical Analysis Perspective, Is NAMS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.